Independent market expert Ratnesh Kumar continues to remain positive on the IT sector, but says pharma as a whole is valuation-wise expensive. He is underweight on the auto-ancillary space and believes it is perhaps done with its best phase
| Subscribe To Our Free Newsletter |
